Hormones are both growth stimulatory and growth inhibitory in utero. They regulate tissue growth and development by controlling the rates of cell proliferation, apoptosis and differentiation in many fetal tissues. They also signal the level of resources available for intrauterine growth to the fe- tal tissues and relay back to the placenta the degree of mismatch between the actual fetal nutrient supply and the fetal nutrient demands for growth. They affect intrauterine growth by anabolic and catabolic actions on fetal metabolism and by altering the nutrient transfer capacity and endocrine function of the placenta. By modifying the fetal growth trajectory, hormones have a central role in programming development in utero and in determining the phenotypic outcome of changes in feto-placental growth during adverse intrauterine conditions. This review examines the role of hormones in feto-placental growth with particular emphasis on insulin, the insulin-like growth factors and glucocorticoids.

Keywords:
Intrauterine growth, programming, Feto-placental growth, Placenta, Fetus, Insulin, Glucocorticoids, Insulin-like growth factors
1.
Barker DJP: Mothers, Babies and Disease in Later Life. London, BMJ Publishing Group, 1994.
2.
McMillen IC, Robinson JS: Developmental origins of the metabolic syndrome: prediction, plasticity and programming. Physiol Rev 2005;85:571–633.
3.
Fowden AL: Endocrine regulation of fetal growth. Reprod Fertil Dev 1995;7:351–363.
4.
Fowden AL, Forhead AJ: Hormones as epigenetic signals in developmental programming. Exp Physiol 2009;94:607–625.
5.
Fowden AL, Forhead AJ: Hormones as nutritional signals and their role in programming intrauterine development; in Barker DJ (ed): Fetal Origins of Cardiovascular and Lung Disease. NIH Monograph. New York, Dekker, 2000, pp 199–228.
6.
Fowden AL, Ward JW, Wooding FPB, Forhead AJ, Constancia M: Programming placental nutrient transfer capacity. J Physiol 2006;572:5–15.
7.
Fowden AL, Forhead AJ: Hormones as epigenetic signals in developmental programming. Exp Physiol 2009;94:607–625.
8.
Fuglsang J, Ovesen P: Aspects of placental growth hormone physiology. Growth Horm IGF Res 2006;16:67–85.
9.
Fowden AL, Forhead AJ: Effects of pituitary hormone deficiency on the growth the glucose metabolism of the sheep fetus. Endocrinology 2007;148:4812–4820.
10.
Fowden AL, Forhead AJ: Endocrine mechanisms of intrauterine programming. Reproduction 2004;127:515–526.
11.
Dunger DB, Petry CJ, Ong KK: Genetics of size at birth. Diabetes Care 2007;30:S150–S155.
12.
Fowden AL, Hughes P, Comline RS: The effects of insulin on the growth rate of the sheep fetus during late gestation. Q J Exp Physiol 1989;74:703–714.
13.
Fowden AL: The role of insulin in prenatal growth. J Dev Physiol 1989;12:173–182.
14.
Fowden AL, Li J, Forhead AJ: Glucocorticoids and the preparation for life after birth: are there long-term consequences of life insurance? Proc Nutr Soc 1998;57:113–122.
15.
Fowden AL, Hay WW: The effects of pancreatectomy on the rates of glucose utilization, oxidation and production in the sheep fetus. Q J Exp Physiol 1988;73:973–984.
16.
Shen W, Wisniowski P, Ahmed L, Boyle DW, Denne SC, Liechty EA: Protein anabolic effects of insulin and IGF-I in the ovine fetus. Am J Physiol 2003;284:E748–E756.
17.
Jansson T, Powell TL: Role of placenta in fetal programming: underlying mechanism and potential intervention approaches. Clin Sci 2007;113:1–13.
18.
Hay WW: Recent observations on the regulation of fetal metabolism by glucose. J Physiol 2006;572:17–24.
19.
Fowden AL: The insulin-like growth factors and feto-placental growth. Placenta 2003;24:803–812.
20.
Efstratiadis A: Genetics of mouse growth. Int J Dev Biol 1998;42:955–976.
21.
Sinclair KD, Lea RG, Rees WD, Young LE: The developmental origin of health and disease: current theories and epigenetic mechanisms. Soc Reprod Fertil Suppl 2007;64:425–443.
22.
Lok F, Owens JA, Mundy L, Robinson JS, Owens PC: Insulin-like growth factor I promotes growth selectively in fetal sheep in late gestation. Am J Physiol 1996;270:R1148–R1155.
23.
Bloomfield FH, van Zigl PL, Bauer MK, Harding JE: A chronic low dose infusion of insulin-like growth factor I alters placental function but does not affect fetal growth. Reprod Fert Dev 2002;14:393–400.
24.
Fowden AL, Sibley C, Reik W, Constancia M: Imprinted gene, placental development and fetal growth. Reprod Fertil Dev 2002;14:393–400.
25.
Han VK, Carter AM: Spatial and temporal patterns of expression of RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals. Placenta 2000;21:289–305.
26.
Lopez MF, Dikkes P, Zurakowski D, Villa-Komaroff L: Insulin-like growth factor II affects the appearance and glycogen content of glycogen cells in the murine placenta. Endocrinology 1996;137:2100–2108.
27.
Sibley CP, Coan PM, Ferguson-Smith AC, Dean W, Hughes J, Smith P, Reik W, Burton GB, Fowden AL, Constancia M: Placental specific insulin-like growth factor-2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci USA 2004;101:8204–8208.
28.
Coan PM, Fowden AL, Constancia M, Ferguson-Smith AC, Burton GJ, Sibley CP: Disproportionate effects of Igf2 gene knockout on placental morphology and diffusional exchange characteristics in the mouse. J Physiol 2008;586:5023–5032.
29.
Constancia M, Angiolini E, Sandovici I, Smith P, Smith R, Kelsey G, Dean W, Ferguson-Smith A, Sibley C, Reik W, Fowden AL: Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the lgf2 gene and placental transporter systems. Proc Natl Acad Sci USA 2005;102:19219–19224.
30.
Bassett JM, Hanson C: Prevention of hypoinsulinaemia modifies catecholamine effects in fetal sheep. Am J Physiol 2000;278:R1171–R1181.
31.
Seckl JR: Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004;151:U49–U62.
32.
Fowden AL, Szemere J, Hughes P, Gilmour RS, Forhead AJ: The effects of cortisol on the growth rate of the sheep fetus during late gestation. J Endocrinol 1996;151:97–105.
33.
Fowden AL, Giussani DA, Forhead AJ: Endocrine and metabolic programming during intrauterine development. Early Hum Dev 2005;81:723–734.
34.
Milley JR: Effects of cortisol concentration on ovine fetal leucine kinetics and protein metabolism. Am J Physiol 1995;268:E1114–E1122.
35.
Timmerman M, Teng C, Wilkening RP, Fennessy P, Battaglia FC, Meschia G: Effect of dexamethasone on fetal hepatic glutamine-glutamate exchange. Am J Physiol 2000;278:E839–E845.
36.
Baisden B, Sonne S, Joshi RM, Ganapathy V, Shekhawat PS: Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta. Placenta 2007;28:1082–1090.
37.
Ward JW, Forhead, AJ, Wooding FBP, Fowden AL: Functional significance and cortisol dependence of the gross morphology of ovine placentomes during late gestation. Biol Reprod 2006;74:137–145.
38.
Fowden AJ, Forhead AJ, Coan PM, Burton GJ: The placental and intrauterine programming. J Neuroendocrinol 2008;20:439–450.
39.
Ward JW, Wooding FPB, Fowden AL: Ovine feto-placental metabolism. J Physiol 2004;554:529–541.
40.
Fowden AL, Hill DJ: Intrauterine programming of the endocrine pancreas. Br Med Bull 2001;60:123–142.
41.
Coulter CL, Ross JT, Owens JA, Bennett HP, McMillen IC: Role of pituitary POMC-peptide and insulin-like growth factor II in the developmental biology of the adrenal gland. Arch Physiol Biochem 2002;110:99–105.
42.
Murphy VE, Smith R, Giles WB, Clifton VL: Endocrine regulation of human fetal growth: the role of the mother, placenta and fetus. Endocr Rev 2006;27:141–169.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.